Wegovy Tablet Results: How Much Weight Can You Lose and How Quickly?

In the OASIS 4 clinical trial, Wegovy tablets containing oral semaglutide 25mg led to average weight loss of 13.6% after 64 weeks. In people who stayed on treatment as planned, average weight loss was 16.6%.

This means a person weighing 100kg could lose around 13.6kg to 16.6kg on average, although individual results can be higher or lower.

*These results came from a clinical trial where participants also received lifestyle support. Wegovy tablets should be used alongside a reduced-calorie diet and increased physical activity.
Source: OASIS 4 Clinical Trial

*These figures are examples based on average percentage weight loss from clinical trial results. They are not a guarantee of your personal result.

Wegovy tablet results usually build gradually. Most people should not expect maximum weight loss in the first few weeks because treatment starts on a low dose and increases slowly.

The OASIS 4 trial reports the main weight loss result at 64 weeks. Monthly results below are estimates based on the trial endpoint and typical dose escalation. They should be used as a guide, not a guaranteed prediction.

*Some people lose weight faster, while others lose weight more slowly. The most important sign is steady progress over time, rather than a dramatic change in the first month

Wegovy tablet results after 1 month

After 1 month, weight loss is usually modest because most people are still on the starting dose. Some people may notice reduced appetite, smaller portion sizes and fewer cravings before they see a major change on the scales.

A realistic expectation after the first month is around 1% to 2% body weight loss, although some people may lose more or less.

Wegovy tablet results after 3 months

After 3 months, many people are moving through the dose escalation schedule and may start to see clearer weight loss. A realistic estimate is around 4% to 6% body weight loss by this stage.

For someone weighing 100kg, this would be around 4kg to 6kg. Results depend heavily on diet, activity, side effects and whether the tablet is being taken correctly.

Wegovy tablet results after 6 months

After 6 months, results are usually more noticeable. A realistic estimate is around 8% to 12% body weight loss, although some people may lose more and others less.

This is often the point where changes in clothing size, waist measurement and appetite control become more obvious.

Wegovy tablet results after 1 year

After around 1 year, many people are closer to their full treatment response. In the OASIS 4 trial, average weight loss reached 13.6% over 64 weeks, or 16.6% in people who stayed on treatment.

This means Wegovy tablets can produce clinically significant weight loss, but results require consistency over many months.

Wegovy tablet before and after results usually show gradual changes rather than sudden transformation. Common changes may include:

• lower body weight
• smaller waist measurement
• reduced appetite
• fewer cravings
• smaller portion sizes
• improved mobility
• improved confidence with diet control

The most reliable way to track results is to record your weight, waist measurement and progress photos at regular intervals. Weekly weigh-ins and monthly photos are usually more useful than checking your weight every day.

Some people lose less weight on Wegovy tablets because results depend on several factors, including dose, adherence, diet, activity levels, side effects and tablet absorption.

Wegovy tablets must be taken correctly to work properly. They should be taken on an empty stomach after fasting, with a small amount of plain water. You should then wait at least 30 minutes before eating, drinking or taking other medicines.

Eating or drinking too soon after taking Wegovy tablets can reduce absorption. This may make treatment less effective.

To get the best results from Wegovy tablets, you should:

• take the tablet exactly as prescribed
• take it on an empty stomach
• use plain water only
• wait at least 30 minutes before food, drink or other medicines
• follow your dose increase schedule
• eat a reduced-calorie diet
• prioritise protein and fibre
• stay hydrated
• increase activity gradually
• speak to your prescriber if side effects affect eating or drinking

Do not increase your dose faster than prescribed. Increasing too quickly can increase side effects and may make treatment harder to continue.

Wegovy tablets and standard Wegovy injections appear to produce broadly similar weight loss results, based on separate clinical trials.

Wegovy tablets 25mg led to average weight loss of 13.6% to 16.6% over 64 weeks. Standard Wegovy injections 2.4mg led to average weight loss of around 14.9% to 15.2% in major trials.

However, higher-dose Wegovy injections may produce greater weight loss. In STEP UP, semaglutide 7.2mg weekly led to average weight loss of 18.7% to 20.7% over 72 weeks.

These studies were not direct head-to-head comparisons, so results should be interpreted with caution.

Further reading: Wegovy tablets vs injections

You should usually judge Wegovy tablet results over several months, not just the first few weeks. Early treatment uses lower doses, so weight loss may be slower at the start.

Many people can assess early progress after 3 months, but the full result is usually judged after longer treatment, especially once the maintenance dose has been reached.

Speak to your prescriber if you are taking Wegovy tablets correctly but not losing weight, or if side effects are preventing you from eating, drinking or continuing treatment safely.

Yes. Wegovy tablet results are clinically significant. In the main OASIS 4 trial, oral semaglutide 25mg helped people lose 13.6% of body weight on average over 64 weeks, rising to 16.6% in people who stayed on treatment.

For many people, this can mean meaningful weight loss. However, results depend on correct use, dose escalation, adherence, lifestyle changes and side effects. Wegovy tablets are not a quick fix, but they can be an effective prescription option for people who want a needle-free GLP-1 treatment.